Last reviewed · How we verify
Prevention of postmenopausal osteoporosis — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Duavee | conjugated-estrogens-bazedoxifene | Pfizer | Estrogen [EPC] | estrogen receptors α and β | 2013-01-01 | |
| Duavee | Bazedoxifene Acetate | Pfizer Inc. | Estrogen agonist/antagonist combination | Estrogen receptors (ER) α and β |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Prevention of postmenopausal osteoporosis
- Pfizer Inc. · 1 drug in Prevention of postmenopausal osteoporosis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Prevention of postmenopausal osteoporosis:
- Prevention of postmenopausal osteoporosis treatment updates — RSS
- Prevention of postmenopausal osteoporosis treatment updates — Atom
- Prevention of postmenopausal osteoporosis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Prevention of postmenopausal osteoporosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-postmenopausal-osteoporosis. Accessed 2026-06-10.
Related
- Prevention of postmenopausal osteoporosis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing